The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).
 
Andrew Wagner
Honoraria - AADi; Cogent Biosciences
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono/Merck; InhibRx; Pharmaessentia; SERVIER
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Rain Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
 
Jonathan Trent
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; SERVIER
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Boehringer Ingelheim; Curadev; Daiichi Sankyo; Deciphera; EMD Serono; Ikena Oncology; inhibrx; Ipsen; Ratio; Recordati; SynOX
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Robin Jones
Consulting or Advisory Role - Adaptimmune; Adcendo; Agenus; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Cogent Biosciences; Daiichi Sankyo; Deciphera; Eisai; Epizyme; GlaxoSmithKline; IDRx; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; NewBay Pharma; Orion Health; PharmaMar; PTC Therapeutics; SERVIER; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Sebastian Bauer
Honoraria - Deciphera; Pharmamar; SpringWorks Therapeutics
Consulting or Advisory Role - Adcendo; Blueprint Medicines; Boehringer Ingelheim; Deciphera; IDRX; Merck
Research Funding - IDRX (Inst); von Pfeffel (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for a drug to treat a sarcoma subtype (Inst)
Travel, Accommodations, Expenses - von Pfeffel Pharmaceuticals
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Von Pfeffel Corporation
Consulting or Advisory Role - deciphera; Von Pfeffel Pharma
Research Funding - ASCO (Inst); Cogent Biosciences (Inst); Deciphera (Inst); IDRx (Inst); Novartis (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; deciphera
Other Relationship - NCCN
 
Michael Heinrich
Stock and Other Ownership Interests - von Pfeffel
Consulting or Advisory Role - Cogent Pharmaceuticals; Deciphera; Natera; New Bay; Novartis; von Pfeffel Pharmaceuticals
Travel, Accommodations, Expenses - Deciphera
 
Min-Hee Ryu
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Breelyn Wilky
Consulting or Advisory Role - AADi; Adcendo; Boehringer Ingelheim; Deciphera; InhibRx; Parabilis; Polaris; SpringWorks Therapeutics
Research Funding - Exelixis
Travel, Accommodations, Expenses - Agenus
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; EMD Serono; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Medilink Therapeutics (Inst); Merck; Neoleukin Therapeutics; Novartis (Inst); Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen; Synox (Inst)
Expert Testimony - EMD Serono/Merck; Medison
 
Omar Khan
Honoraria - AstraZeneca Canada; Gilead Sciences; Merck; Novartis Canada Pharmaceuticals Inc
Consulting or Advisory Role - AstraZeneca Canada; Gilead Sciences; Knight Therapeutics; Pfizer
Research Funding - Altis Labs (Inst); Breast Cancer Society of Canada (Inst); Cogent Biosciences (Inst)
 
Felipe Eduardo Pinto Negrete
No Relationships to Disclose
 
Amanda Pilla
Employment - Cogent Biosciences
 
Zahabia Adenwala
Employment - Cogent Biosciences
 
Celeste LaHaie
Employment - Cogent Biosciences
 
Liangxing Zou
Employment - Cogent Biosciences
 
Lei Sun
Employment - Cogent Biosciences
 
Rachael Easton
Employment - Cogent Biosciences
 
Jessica Sachs
Employment - Cogent Biosciences
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Boehringer Ingelheim; Deciphera; Ipsen; Replimune
Research Funding - Advenc (Inst); Ascentage Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Karyopharm Therapeutics (Inst)